HBP:CC - Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw as Chief Medical Officer
(TheNewswire)
October 3, 2022 – TheNewswire - Toronto, Ontario – Helix BioPharmaCorp . (TSX:HBP) (OTC:HBPCF) (“Helix”or the “Company”), a clinical-stage biopharmaceutical company thatis developing unique therapies in the field of immuno-oncology basedon its proprietary technology platform DOS47, is pleased to announcethe appointment of Dr. Frank Gary Renshaw, as the Chief MedicalOfficer.
Dr. Renshaw has been with Helix since December 2019 asa consultant and member of the Scientific and Strategic AdvisoryBoard. He brings more than 20 years’ experience as a drug developerwithin the health care industry and has previously provided leadershipwith his medical and/or scientific expertise, from pre-clinicallaboratory and animal tumor model development, to presiding over sixsuccessful new drug applications, eight approvals at the EMA,including two biological applications, and more than two dozensuccessful FIH IND’s and EMA new drug submissions.
Recently, he has provided further expertise as theChief Medical Officer, and lead Oncology consultant for severalBio-Pharmaceutical global entities, as well as the Global lead on manyradiotherapies, Chemotherapy, Devices, and Immuno-Oncology clinicalprograms.
“Dr. Renshaw will bring to Helix BioPharma hisseveral decades of development experience in oncology-hematology,Molecular/Immuno-Oncology drug research. We look forward to hisleadership in helping shape the future of our work at Helix.”, saidArtur Gabor, Helix’s Chief Executive Officer.
Dr. Renshaw stated," L-DOS47 has the potential to enhance theefficacy of chemo- and IO-therapies for treatment of various tumors bymodulating the tumor microenvironment. *With promising data alreadygenerated from preclinical experiments and previous clinical trials, Iam excited to lead the next phase of clinical development to bringthis improved therapy for cancer patients at the earliest.”
Frank Gary Renshaw Bio
Dr. Frank Gary Renshaw is an Oncologist-Hematologisthaving completed his training at the medical school at University ofMedicine and Dentistry of New Jersey at the Cardeza Foundation andTemple University Skin and Cancer Hospital and was a resident withinthe Oncology immunology research group at the Cancer Institute of NJ.Subsequent to this, he trained during his Oncology fellowship with theCancer Immuno-Biological therapy group at MD Anderson Cancer Centerand completed a molecular Biology fellowship at the NIH Naval Medicalcenter where he worked on FIH trials of T-Cell therapy. During hisacademic career he worked as an Oncology consultant and Primaryinvestigator to the Glaxo Smith Kline, Immunex, Chiron, Bristol MyersSquibb, and Sinclair Swine melanoma research, companies. From hisacademic rolls, Dr. Renshaw was then recruited to chair the USGastrointestinal Oncology group at Eli Lilly company, leading severalearly development programs as well as the later stages of drugclinical/research development of Gemcitabine, and includingpharmacogenetic/dynamics work for the eventual multiple approvalsPemetrexed for NSCLC and Mesothelioma.
Helix BioPharma Corp. is a clinical-stagebiopharmaceutical company developing unique therapies in the field ofimmune-oncology for the prevention and treatment of cancer, based onthe proprietary technology platform DOS47. Helix is listed on the TSXunder the symbol “HBP.”
For more information, please contact:
Helix BioPharma Corp.
Suite 2704, 401 Bay Street Toronto, Ontario, M5H 2Y4
Tel: 905-841-2300
Namrata Malhotra, CorporateSecretary
Forward-LookingStatements and Risks and Uncertainties
This news release containsforward-looking statements and information (collectively,“forward-looking statements”) within the meaning of applicableCanadian securities laws. Forward-looking statements are statementsand information that are not historical facts but instead includefinancial projections and estimates, statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to DOS47, and statementsregarding expected improvements to the Company’s independence,diversification and corporate governance and the Company’sexpectations regarding strengthening its future growth capabilities.Forward-looking statements can further be identified by the use offorward-looking terminology such as “ongoing”, “estimates”,“expects”, or the negative thereof or any other variations thereonor comparable terminology referring to future events or results, orthat events or conditions “will”, “may”, “could”, or“should” occur or be achieved, or comparable terminology referringto future events or results.
Forward-looking statements arestatements about the future and are inherently uncertain and arenecessarily based upon a number of estimates and assumptions that arealso uncertain. Although the Company believes that the expectationsreflected in such forward- looking statements are reasonable, suchstatements involve risks and uncertainties, and undue reliance shouldnot be placed on such statements. Forward-looking statements,including financial outlooks, are intended to provide informationabout management’s current plans and expectations regarding futureoperations, including without limitation, future financingrequirements, and may not be appropriate for other purposes. Certainmaterial factors, estimates or assumptions have been applied in makingforward-looking statements in this news release.
The Company’s actual results coulddiffer materially from those anticipated in the forward-lookingstatements contained in this news release as a result of numerousknown and unknown risks and uncertainties, including withoutlimitation; the risk that the Company’s assumptions may prove to beincorrect; the risk that additional financing may not be obtainable ina timely manner, or at all, and that clinical trials may not commenceor complete within anticipated timelines or the anticipated budget ormay fail; third party suppliers of necessary services or of drugproduct and other materials may fail to perform or be unwilling orunable to supply the Company, which could cause delay or cancellationof the Company’s research and development activities; necessaryregulatory approvals may not be granted or may be withdrawn; theCompany may not be able to secure necessary strategic partner support;general economic conditions, intellectual property and insurancerisks; changes in business strategy or plans; and other risks anduncertainties referred to elsewhere in this news release, any of whichcould cause actual results to vary materially from current results orthe Company’s anticipated future results. Certain of these risks anduncertainties, and others affecting the Company, are more fullydescribed in the Company’s annual management’s discussion andanalysis for the year ended July 31, 2021 under the heading “Risksand Uncertainties” and Helix’s Annual Information Form, inparticular under the headings “Forward-looking Statements” and“Risk Factors”, and other reports filed under the Company’sprofile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information arebased on the beliefs, assumptions, opinions and expectations ofHelix’s management on the date of this new release, and the Companydoes not assume any obligation to update any forward-looking statementor information should those beliefs, assumptions, opinions orexpectations, or other circumstances change, except as required bylaw.
Copyright (c) 2022 TheNewswire - All rights reserved.